...
首页> 外文期刊>Journal of pharmaceutical sciences. >Tableting lipid-based formulations for oral drug delivery: A case study with silica nanoparticle-lipid-mannitol hybrid microparticles
【24h】

Tableting lipid-based formulations for oral drug delivery: A case study with silica nanoparticle-lipid-mannitol hybrid microparticles

机译:用于口服药物递送的压片基脂质制剂:用二氧化硅纳米粒子 - 脂质 - 甘露醇杂交微粒进行案例研究

获取原文
获取原文并翻译 | 示例
           

摘要

Silica-lipid-mannitol hybrid (SLMH) microparticles have been developed that were compressible into high quality tablets suitable for oral dosing and delivery of poorly soluble drugs. SLMH tablets enable high lipid-loading levels (>40%) and retain the immediate release, enhanced lipase digestion and drug solubilisation performance. Specifically, we report formulation optimisation of SLMH microparticles and tablets using coumarin 102 (log P = 4.09) as a model Biopharmaceutics Classification System class II drug. SLMH tablets were acceptable according to standard British Pharmacopoeia friability, hardness and disintegration tests; this is not the case for conventional dry emulsions. Furthermore, in vitro dissolution and pancreatic-lipase-induced lipolysis studies under simulated intestinal conditions have demonstrated enzymatic-digestion-mediated drug solubilisation. SLMH microparticles and tablets are suitable as liquid lipid containing solid dosage forms for enhancing and controlling oral absorption of poorly soluble drugs.
机译:已经开发了二氧化硅 - 脂质 - 甘露醇杂交(SLMH)微粒,其可压缩成适合于口服给药和递送差不可溶的药物的高质量片剂。 SLMH片剂使高脂质加载水平(> 40%),并保留立即释放,增强脂肪酶消化和药物溶解性能。具体而言,我们通过香豆素102(log p = 4.09)作为模型生物制药学分类系统II类药物的药物,报告SLMH微粒和片剂的配方优化。根据标准的英国药典脆性,硬度和崩解试验,SLMH片剂可接受;常规干乳液不是这种情况。此外,在模拟肠道条件下的体外溶解和胰腺 - 脂肪酶诱导的脂解性研究已经表明了酶消化介导的药物溶解。 SLMH微粒和片剂适合作为含有固体剂型的液体脂质,用于增强和控制恶性药物的口服吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号